Clinical Trials

  • Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy

    The objectives of this dose-finding study for the treatment of peanut allergy are:

    - To determine the efficacy of 3 doses of Viaskin Peanut (50 mcg ,100 mcg and 250 mcg peanut protein per patch) to significantly desensitize peanut-allergic subjects to peanut after 12 months of treatment.

    - To evaluate the safety of a long-term treatment with Viaskin Peanut.

    Investigator

    Now accepting new patients View Details
  • Safety Study of Viaskin Peanut to Treat Peanut Allergy

    This study evaluates the safety of Viaskin Peanut 250 mcg in the treatment of peanut allergy in children from 4 to 11 years of age. Subjects will receive either Viaskin Peanut 250 mcg or a placebo for a period of 6 months, after which all subjects will be receiving the active treatment up to a period of 3 years under active treatment.

    Investigator

    Now accepting new patients View Details
  • Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial

    The investigators will perform a double blind, placebo controlled clinical trial with Xolair (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut allergy. The investigators will determine if pretreatment with anti-IgE mAb (Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer desensitization.

    Now accepting new patients View Details
  • Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)

    Background:

    PANS is an illness that comes on suddenly in children. The full name is Pediatric Acute-Onset Neuropsychiatric Syndrome. It can cause sudden obsessive-compulsive behaviors. It can also cause children to suddenly restricte their food intake. Researchers want to learn more about children with PANS. They also want to learn more about the illness.

    Objective:

    To study some disorders of behavior and emotion that start in childhood.

    Eligibility:

    Children 3 14 years old who have had severe obsessive-compulsive symptoms or food restriction start quickly

    Design:

    Parents will answer questions. The topics include:

    Their child s medical history

    Their child s physical and mental health

    Their family history. The focus will be on neurodevelopmental and psychiatric conditions. A family tree will be drawn.

    Participants will have a physical exam.

    Participants may take tests on paper or computer. These will focus on thinking, memory, and behavior.

    Participants and parents will give a blood sample.

    Participants will have magnetic resonance imaging (MRI). A strong magnetic field and radio waves take pictures of the brain. Participants will lie on a table that slides in and out of a metal scanner.

    Participants may have photos or videos taken.

    Participants may have other tests. These may include heart tests, sleep tests, and lumbar puncture.

    Sponsoring Institute: National Institute of Mental Health

    Now accepting new patients View Details
  • Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single Site

    This is a protocol for prescreening of participants who would like to be in clinical studies in our Center at Stanford.

    Now accepting new patients View Details
  • Clinical Study Using Biologics to Improve Multi OIT Outcomes

    Food allergy (FA) is a serious public health concern that causes potentially-life threatening reactions in affected patients. The prevalence of food allergy in the United States (U.S.) has increased substantially and now affects 15 million patients:4-8% of children (6 million children, 30% with multiple food allergies) and about 9% of adults. This is a prospective Phase 2, single-center, multi-allergen OIT study in participants with proven allergies to 2 or 3 different foods in which one must be a peanut. The total of participants in the clinical study will be 110, ages 5 to 55 years with a history of multiple food allergies of 2 to 3 different foods including peanut. Allergy will be confirmed by FA-specific IgE levels and positive skin prick test (SPT). Enrolled participants must be positive during the Double-blind Placebo-controlled Food challenge (DBPCFC) at or before the 300 mg (444 mg cumulative) dosing level of FA proteins.

    Now accepting new patients View Details
  • Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine

    Concomitant administration of multiple vaccines, including live attenuated immunizations, is safe and effective. Some restrictions apply for live vaccines; administering a live-virus vaccine within 4 weeks after administration of another live-virus vaccine can decrease immunogenicity to the second administered vaccine. Thus, it is recommended that live-virus vaccines should be administered the same day or ≥4 weeks apart. Data on co-administration of the currently available whole-cell killed Oral Cholera Vaccine (OCVs) with other oral vaccines, specifically, oral polio vaccines (OPV) is lacking. Although the risk of immunological interference due to co-administration of live vaccines with non-live vaccines is considered small if at all, a theoretical concern of interference has been raised. Given the substantial geographic correlation between polio- and cholera-affected and at-risk areas, which include some of the world's most impoverished and hard-to-reach populations, a strategy of co-administration of OCV with OPV to children targeted to receive OPVs has the potential to optimize the use of limited resources and improve coverage for both vaccines. The manufacturer recommendation for a two-week interval between administration of OPV and OCV precludes an integrated campaign or routine use in which OCV could be co-administered with OPV.

    Now accepting new patients View Details

Please see a full listing of Stanford's clinical trials here.

Use the ClinicalTrials.gov directory to search among all government-funded clinical trials.